{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:06:57Z","timestamp":1791313617091,"version":"4.3.1"},"reference-count":105,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002387","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA16056"],"award-info":[{"award-number":["CA16056"]}],"id":[{"id":"10.13039\/501100002387","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Szefel Foundation"},{"DOI":"10.13039\/100006398","name":"Roswell Park Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006398","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leonard S. LuVullo Endowment for Leukemia Research"},{"name":"Nancy C. Cully Endowment for Leukemia Research"},{"name":"Babcock Family Endowment"},{"name":"Heidi Leukemia Research Fund"},{"DOI":"10.13039\/501100002387","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016056"],"award-info":[{"award-number":["P30CA016056"]}],"id":[{"id":"10.13039\/501100002387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.blre.2015.01.001","type":"journal-article","created":{"date-parts":[[2015,1,10]],"date-time":"2015-01-10T15:35:53Z","timestamp":1420904153000},"page":"243-249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Lin","family":"Mei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelena P.","family":"Ontiveros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meir","family":"Wetzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2015.01.001_bb0005","series-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"10.1016\/j.blre.2015.01.001_bb0010","series-title":"International Agency for Research on Cancer. World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.blre.2015.01.001_bb0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.blre.2015.01.001_bb0020","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/cncr.25690","article-title":"Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives","volume":"117","author":"Lee","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0025","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","article-title":"Acute lymphoblastic leukaemia","volume":"371","author":"Pui","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2015.01.001_bb0030","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.01.001_bb0035","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1016\/S0140-6736(12)62187-4","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2015.01.001_bb0040","doi-asserted-by":"crossref","first-page":"858","DOI":"10.6004\/jnccn.2012.0089","article-title":"Acute lymphoblastic leukemia","volume":"10","author":"Alvarnas","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.blre.2015.01.001_bb0045","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ng.763","article-title":"Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia","volume":"43","author":"Yang","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.blre.2015.01.001_bb0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncr.25489","article-title":"l-Asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase","volume":"117","author":"Pieters","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0055","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fgene.2012.00249","article-title":"Impact of genetic polymorphisms on chemotherapy toxicity in childhood acute lymphoblastic leukemia","volume":"3","author":"Gervasini","year":"2012","journal-title":"Front Genet"},{"key":"10.1016\/j.blre.2015.01.001_bb0060","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/14712590802586058","article-title":"Pegasparaginase: where do we stand?","volume":"9","author":"Zeidan","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0065","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0070","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00043426-200404000-00002","article-title":"Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961","volume":"26","author":"Panosyan","year":"2004","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.blre.2015.01.001_bb0075","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1592\/phco.23.9.3S.32886","article-title":"Pegylation: engineering improved biopharmaceuticals for oncology","volume":"23","author":"Molineux","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.blre.2015.01.001_bb0080","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/MOP.0b013e32833fde85","article-title":"Pharmacogenomics in pediatric leukemia","volume":"22","author":"Paugh","year":"2010","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.blre.2015.01.001_bb0085","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003088-200544040-00003","article-title":"Pharmacokinetic\/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future","volume":"44","author":"Avramis","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.blre.2015.01.001_bb0090","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1182\/blood-2013-10-534347","article-title":"A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia","volume":"123","author":"Tong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0095","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/pbc.21213","article-title":"Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines","volume":"50","author":"Su","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0100","doi-asserted-by":"crossref","first-page":"C1691","DOI":"10.1152\/ajpcell.1997.272.5.C1691","article-title":"Amino acid control of asparagine synthetase: relation to asparaginase resistance in human leukemia cells","volume":"272","author":"Hutson","year":"1997","journal-title":"Am J Physiol"},{"key":"10.1016\/j.blre.2015.01.001_bb0105","doi-asserted-by":"crossref","first-page":"5883","DOI":"10.1182\/blood-2011-05-355560","article-title":"ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia","volume":"118","author":"Rousseau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0110","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.leukres.2013.10.027","article-title":"Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment","volume":"38","author":"Pastorczak","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2015.01.001_bb0115","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/clpt.2010.94","article-title":"Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity","volume":"88","author":"Chen","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0120","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.it.2007.07.005","article-title":"The emergence of neurotransmitters as immune modulators","volume":"28","author":"Franco","year":"2007","journal-title":"Trends Immunol"},{"key":"10.1016\/j.blre.2015.01.001_bb0125","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2014-03-563742","article-title":"HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies","volume":"124","author":"Fernandez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0130","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1056\/NEJMoa0706135","article-title":"HLA-B*5701 screening for hypersensitivity to abacavir","volume":"358","author":"Mallal","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2015.01.001_bb0135","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.2217\/pgs.12.108","article-title":"HLA and pharmacogenetics of drug hypersensitivity","volume":"13","author":"Pavlos","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.blre.2015.01.001_bb0140","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","article-title":"Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo","volume":"97","author":"Hoffmeyer","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2015.01.001_bb0145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2133\/dmpk.23.223","article-title":"Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs","volume":"23","author":"Maeda","year":"2008","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.blre.2015.01.001_bb0150","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0022-3565(24)29643-9","article-title":"Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene","volume":"297","author":"Tanabe","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0155","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/sj.leu.2402545","article-title":"Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes","volume":"16","author":"Lauten","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.01.001_bb0160","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/pbc.22163","article-title":"Response to glucocorticoids and toxicity in childhood acute lymphoblastic leukemia: role of polymorphisms of genes involved in glucocorticoid response","volume":"53","author":"Marino","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0165","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/sj.leu.2403521","article-title":"The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia","volume":"18","author":"Meissner","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.01.001_bb0170","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/jnci\/djn416","article-title":"The SWI\/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia","volume":"100","author":"Pottier","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.blre.2015.01.001_bb0175","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nm.1900","article-title":"Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia","volume":"15","author":"Real","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2015.01.001_bb0180","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1182\/blood-2008-05-157842","article-title":"Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells","volume":"113","author":"Hulleman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0185","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/pbc.22541","article-title":"XIAP expression is post-transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T-cell ALL","volume":"55","author":"Hundsdoerfer","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0190","doi-asserted-by":"crossref","first-page":"20502","DOI":"10.1074\/jbc.M114.569889","article-title":"Loss of TBL1XR1 disrupts glucocorticoid receptor recruitment to chromatin and results in glucocorticoid resistance in a B-lymphoblastic leukemia model","volume":"289","author":"Jones","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.blre.2015.01.001_bb0195","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/leu.2014.80","article-title":"EMP1, a novel poor prognostic factor in pediatric leukemia regulates prednisolone resistance, cell proliferation, migration and adhesion","volume":"28","author":"Aries","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.blre.2015.01.001_bb0200","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/FPC.0b013e3282fc5801","article-title":"Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia","volume":"18","author":"Kamdem","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.blre.2015.01.001_bb0205","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2007.14.6399","article-title":"CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia","volume":"26","author":"Jones","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.01.001_bb0210","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2000.18.18.3262","article-title":"Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group","volume":"18","author":"Mattano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.01.001_bb0215","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1517\/14656566.2010.484019","article-title":"Pharmacogenomics of pediatric acute lymphoblastic leukemia","volume":"11","author":"Meeker","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.blre.2015.01.001_bb0220","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1200\/JCO.2004.11.020","article-title":"Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia","volume":"22","author":"Relling","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.01.001_bb0225","doi-asserted-by":"crossref","first-page":"4496","DOI":"10.1182\/blood-2007-11-123885","article-title":"A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group","volume":"111","author":"French","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0230","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1182\/blood-2010-10-311969","article-title":"Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia","volume":"117","author":"Kawedia","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0235","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.ejca.2010.03.026","article-title":"Mechanisms of dexamethasone-induced disturbed sleep and fatigue in paediatric patients receiving treatment for ALL","volume":"46","author":"Vallance","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0240","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V122.21.59.59","article-title":"High intra-individual variability in systemic exposure to 6 mercaptopurine (6MP) in children with Acute Lymphoblastic Leukemia (ALL) contributes to ALL relapse: results from a Children's Oncology Group (COG) Study (AALL03N1)","volume":"122","author":"Landier","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0245","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/clpt.2011.126","article-title":"Cancer pharmacogenomics","volume":"90","author":"Paugh","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0250","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0255","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMra023001","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2015.01.001_bb0260","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00007691-199608000-00003","article-title":"Individualizing therapy with 6-mercaptopurine and 6-thioguanine related to the thiopurine methyltransferase genetic polymorphism","volume":"18","author":"Lennard","year":"1996","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.blre.2015.01.001_bb0265","first-page":"309","article-title":"Multilocus genotypes of relevance for drug metabolizing enzymes and therapy with thiopurines in patients with acute lymphoblastic leukemia","volume":"3","author":"Stocco","year":"2012","journal-title":"Front Genet"},{"key":"10.1016\/j.blre.2015.01.001_bb0270","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1182\/blood-2004-04-1616","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital","volume":"104","author":"Pui","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0275","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1517\/14740330903426151","article-title":"Genetic polymorphism of inosine\u2013triphosphate\u2013pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status","volume":"9","author":"Stocco","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.blre.2015.01.001_bb0280","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/clpt.2008.154","article-title":"Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia","volume":"85","author":"Stocco","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0285","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00280-009-1205-4","article-title":"The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia","volume":"66","author":"Adam de Beaumais","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2015.01.001_bb0290","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00228-012-1251-4","article-title":"Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia","volume":"68","author":"Adam de Beaumais","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.blre.2015.01.001_bb0295","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1373\/clinchem.2004.039685","article-title":"Rapid detection of ITPA 94C>A and IVS2+21A>C gene mutations by real-time fluorescence PCR and in vitro demonstration of effect of ITPA IVS2+21A>C polymorphism on splicing efficiency","volume":"50","author":"Heller","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.blre.2015.01.001_bb0300","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2174\/138920009789375414","article-title":"Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising","volume":"10","author":"Gervasini","year":"2009","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.blre.2015.01.001_bb0305","first-page":"3790","article-title":"Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells","volume":"55","author":"Moscow","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2015.01.001_bb0310","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM199610033351408","article-title":"Intrinsic and acquired resistance to methotrexate in acute leukemia","volume":"335","author":"Gorlick","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2015.01.001_bb0315","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/mgme.2000.3034","article-title":"A polymorphism (80G\u2192A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia","volume":"70","author":"Chango","year":"2000","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.blre.2015.01.001_bb0320","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood.V100.10.3832","article-title":"Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia","volume":"100","author":"Laverdiere","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0325","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","article-title":"Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia","volume":"121","author":"Radtke","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0330","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00277-007-0274-x","article-title":"Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia","volume":"86","author":"Pakakasama","year":"2007","journal-title":"Ann Hematol"},{"key":"10.1016\/j.blre.2015.01.001_bb0335","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","article-title":"Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects","volume":"27","author":"Trevino","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.01.001_bb0340","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","article-title":"Genome-wide study of methotrexate clearance replicates SLCO1B1","volume":"121","author":"Ramsey","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0345","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/pbc.23074","article-title":"Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia","volume":"57","author":"Lopez-Lopez","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","article-title":"Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition","volume":"22","author":"Ramsey","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.blre.2015.01.001_bb0355","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-013-1623-4","article-title":"Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level?","volume":"70","author":"Kodidela","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.blre.2015.01.001_bb0360","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/10428190902893819","article-title":"Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"50","author":"Kantar","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2015.01.001_bb0365","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00280-011-1665-1","article-title":"Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants","volume":"68","author":"D'Angelo","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2015.01.001_bb0370","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.critrevonc.2012.04.003","article-title":"Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia\/lymphoma","volume":"84","author":"Vagace","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.blre.2015.01.001_bb0375","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3109\/10428194.2013.825902","article-title":"Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients","volume":"55","author":"Tanaka","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.blre.2015.01.001_bb0380","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2003.07.056","article-title":"Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia","volume":"21","author":"Kishi","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2015.01.001_bb0385","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/0008-5472.CAN-04-2606","article-title":"Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia","volume":"65","author":"Aplenc","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2015.01.001_bb0390","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.leukres.2007.03.028","article-title":"MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients","volume":"31","author":"Chiusolo","year":"2007","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2015.01.001_bb0395","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(02)08065-0","article-title":"Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia","volume":"359","author":"Krajinovic","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2015.01.001_bb0400","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/sj.tpj.6500332","article-title":"Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis","volume":"5","author":"Krajinovic","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.blre.2015.01.001_bb0405","first-page":"353","article-title":"Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia","volume":"88","author":"Lauten","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2015.01.001_bb0410","doi-asserted-by":"crossref","first-page":"13513","DOI":"10.1073\/pnas.0706217104","article-title":"A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance","volume":"104","author":"Mishra","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2015.01.001_bb0415","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FPC.0b013e32835c3b24","article-title":"Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia","volume":"23","author":"Lopez-Lopez","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.blre.2015.01.001_bb0420","doi-asserted-by":"crossref","first-page":"e91261","DOI":"10.1371\/journal.pone.0091261","article-title":"Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia","volume":"9","author":"Lopez-Lopez","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2015.01.001_bb0425","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1124\/dmd.106.009902","article-title":"Selective metabolism of vincristine in vitro by CYP3A5","volume":"34","author":"Dennison","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.blre.2015.01.001_bb0430","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/pbc.21435","article-title":"Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients","volume":"50","author":"Renbarger","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0435","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1600-0609.2011.01608.x","article-title":"The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia","volume":"86","author":"Borst","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2015.01.001_bb0440","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/pbc.22845","article-title":"Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia","volume":"56","author":"Egbelakin","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0445","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.leukres.2009.04.027","article-title":"Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia","volume":"34","author":"Hartman","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.blre.2015.01.001_bb0450","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.clpt.2004.05.007","article-title":"Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukemia","volume":"76","author":"Plasschaert","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0455","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1440-1754.2011.02103.x","article-title":"Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach","volume":"47","author":"Moore","year":"2011","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.blre.2015.01.001_bb0460","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood.V122.21.618.618","article-title":"Genome-wide association analyses identify susceptibility loci for vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia","volume":"122","author":"Crews","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0465","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0470","first-page":"3983","article-title":"Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience","volume":"93","author":"Wetzler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0475","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2013-09-529008","article-title":"UKALLXII\/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia","volume":"123","author":"Fielding","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0480","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood-2013-06-509794","article-title":"IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL","volume":"123","author":"van der Veer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0485","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s00280-004-0876-0","article-title":"Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group","volume":"55","author":"Judson","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.blre.2015.01.001_bb0490","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s12185-012-1142-6","article-title":"Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia","volume":"96","author":"Kong","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.blre.2015.01.001_bb0495","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bcmd.2011.11.001","article-title":"ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib","volume":"48","author":"Vivona","year":"2012","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.blre.2015.01.001_bb0500","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","article-title":"Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype","volume":"82","author":"Gurney","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0505","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","article-title":"Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib","volume":"80","author":"Gardner","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2015.01.001_bb0510","doi-asserted-by":"crossref","first-page":"7102","DOI":"10.1158\/1078-0432.CCR-08-0950","article-title":"Population pharmacokinetics and pharmacogenetics of imatinib in children and adults","volume":"14","author":"Petain","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.blre.2015.01.001_bb0515","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","article-title":"Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation","volume":"99","author":"Hofmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2015.01.001_bb0520","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","volume":"120","author":"Soverini","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.blre.2015.01.001_bb0525","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ajmg.c.31391","article-title":"PG4KDS: a model for the clinical implementation of pre-emptive pharmacogenetics","volume":"166C","author":"Hoffman","year":"2014","journal-title":"Am J Med Genet C Semin Med Genet"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X15000028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X15000028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T17:38:16Z","timestamp":1747417096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X15000028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":105,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0268960X15000028"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2015.01.001","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2015.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}